U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C6H13NO5.2Cl.2K.H2O4S
Molecular Weight 605.523
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLUCOSAMINE SULFATE POTASSIUM CHLORIDE

SMILES

[Cl-].[Cl-].[K+].[K+].OS(O)(=O)=O.N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO.N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO

InChI

InChIKey=ZGYRLIPOHALCCV-VQRMJQQYSA-L
InChI=1S/2C6H13NO5.2ClH.2K.H2O4S/c2*7-3(1-8)5(11)6(12)4(10)2-9;;;;;1-5(2,3)4/h2*1,3-6,9-12H,2,7H2;2*1H;;;(H2,1,2,3,4)/q;;;;2*+1;/p-2/t2*3-,4+,5+,6+;;;;;/m00...../s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula O4S
Molecular Weight 96.063
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H13NO5
Molecular Weight 179.1711
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Glucosamine is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids. Glucosamine is part of the structure of the polysaccharides chitosan and chitin, which compose the exoskeletons of crustaceans and other arthropods, as well as the cell walls of fungi and many higher organisms. Glucosamine is one of the most abundant monosaccharides. It is produced commercially by the hydrolysis of crustacean exoskeletons or, less commonly, by fermentation of a grain such as corn or wheat. Oral glucosamine is a dietary supplement and is not a pharmaceutical drug. It is illegal in the US to market any dietary supplement as a treatment for any disease or condition. Glucosamine is marketed to support the structure and function of joints, and the marketing is targeted to people suffering from osteoarthritis. Commonly sold forms of glucosamine are glucosamine sulfate, glucosamine hydrochloride, and N-acetylglucosamine. Of the three commonly available forms of glucosamine, only glucosamine sulfate is given a "likely effective" rating for treating osteoarthritis. Glucosamine is often sold in combination with other supplements such as chondroitin sulfate and methylsulfonylmethane. Glucosamine, along with commonly used chondroitin, is not routinely prescribed to treat people who have symptomatic osteoarthritis of the knee, as there is insufficient evidence that this treatment is helpful. One clinical study over three years showed that glucosamine in doses of 1500 mg per day is safe to use. Glucosamine with or without chondroitin elevates the international normalized ratio (INR) in individuals who are taking the blood thinner, warfarin. It may also interfere with the efficacy of chemotherapy for treating cancer symptoms. Adverse effects may include stomach upset, constipation, diarrhea, headache, and rash. There are case reports of people who have chronic liver disease and a worsening of their condition with glucosamine supplementation. Glucosamine is naturally present in the shells of shellfish, animal bones, bone marrow, and fungi. D-Glucosamine is made naturally in the form of glucosamine-6-phosphate, and is the biochemical precursor of all nitrogen-containing sugars. Specifically in humans, glucosamine-6-phosphate is synthesized from fructose 6-phosphate and glutamine by glutamine—fructose-6-phosphate transaminase as the first step of the hexosamine biosynthesis pathway. The end-product of this pathway is uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), which is then used for making glycosaminoglycans, proteoglycans, and glycolipids. As the formation of glucosamine-6-phosphate is the first step for the synthesis of these products, glucosamine may be important in regulating their production; however, the way that the hexosamine biosynthesis pathway is actually regulated, and whether this could be involved in contributing to human disease remains unclear.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Glucosamine

Approved Use

Unknown
Primary
Glucosamine

Approved Use

Unknown
Primary
Oral Lichen Planus

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
[Experience with glucosamine hydrochloride in the treatment of patients with osteoarthrosis].
2005
Inhibitory effects of glucosamine on lipopolysaccharide-induced activation in microglial cells.
2005 Dec
Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta.
2006
Double blind investigation of the effects of oral supplementation of combined glucosamine hydrochloride (GHCL) and chondroitin sulphate (CS) on stride characteristics of veteran horses.
2006 Aug
Arthritic disease suppression and cartilage protection with glycosaminoglycan polypeptide complexes (Peptacans) derived from the cartilage extracellular matrix: a novel approach to therapy.
2006 Aug
Glucosamine sulfate inhibits proinflammatory cytokine-induced icam-1 production in human conjunctival cells in vitro.
2006 Dec
Enhanced chondrogenic differentiation of murine embryonic stem cells in hydrogels with glucosamine.
2006 Dec
Glucosamine sulfate inhibits TNF-alpha and IFN-gamma-induced production of ICAM-1 in human retinal pigment epithelial cells in vitro.
2006 Feb
Determination of the degree of acetylation of chitosan by UV spectrophotometry using dual standards.
2006 May 1
An optimized reverse-phase high performance liquid chromatographic method for evaluating percutaneous absorption of glucosamine hydrochloride.
2006 May 3
Glucosamine sulfate inhibits leukocyte adhesion in response to cytokine stimulation of retinal pigment epithelial cells in vitro.
2006 Nov
[The influence of experimental therapy on the dynamics of endogenous glucosamine content in laboratory animals with nephropathy].
2006 Nov-Dec
Evidence-based practice: review of clinical evidence on the efficacy of glucosamine and chondroitin in the treatment of osteoarthritis.
2006 Oct
Glucosamine sulfate-induced apoptosis in chronic myelogenous leukemia K562 cells is associated with translocation of cathepsin D and downregulation of Bcl-xL.
2006 Oct
An analysis of high glucose and glucosamine-induced gene expression and oxidative stress in renal mesangial cells.
2006 Oct-Dec
Glucosamine hydrochloride for the treatment of osteoarthritis symptoms.
2007
Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study.
2007
Glucosamine affects intracellular signalling through inhibition of mitogen-activated protein kinase phosphorylation in human chondrocytes.
2007
Glucosamine prevents in vitro collagen degradation in chondrocytes by inhibiting advanced lipoxidation reactions and protein oxidation.
2007
Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis.
2007
Establishment of a novel corneal endothelial cell line from domestic rabbit, Oryctolagus curiculus.
2007 Apr
[A comparison study on the physical/chemical properties and immunomodulatory activities of mycelial polysaccharide extracts from five Ganoderma species].
2007 Aug
Modulation of articular chondrocyte proliferation and anionic glycoconjugate synthesis by glucosamine (GlcN), N-acetyl GlcN (GlcNAc) GlcN sulfate salt (GlcN.S) and covalent glucosamine sulfates (GlcN-SO4).
2007 Aug
Systematic review of clinical trials of treatments for osteoarthritis in dogs.
2007 Feb 15
Factors affecting trypanosome maturation in tsetse flies.
2007 Feb 21
Effects of glucosamine administration on patients with rheumatoid arthritis.
2007 Jan
Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions.
2007 Jul
Glucosamine for pain in osteoarthritis: why do trial results differ?
2007 Jul
[Efficacy and safety evaluation of glucosamine hydrochloride in the treatment of osteoarthritis].
2007 Jul 15
Sulfated glucosamine inhibits MMP-2 and MMP-9 expressions in human fibrosarcoma cells.
2007 Jul 15
Collagen Synthesis in tenocytes, ligament cells and chondrocytes exposed to a combination of Glucosamine HCl and chondroitin sulfate.
2007 Jun
Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation.
2007 Jun
Preparation of glucosamine from exoskeleton of shrimp and predicting production yield by response surface methodology.
2007 Mar 21
The effects of glucosamine hydrochloride on subchondral bone changes in an animal model of osteoarthritis.
2007 May
Glucosamine inhibits LPS-induced COX-2 and iNOS expression in mouse macrophage cells (RAW 264.7) by inhibition of p38-MAP kinase and transcription factor NF-kappaB.
2007 May
[Effect of glucosamine sulfate on the analgesic and ulcerogenic activity of ketoprofen].
2007 May-Jun
[Determination of glucosamine hydrochloride in complex formula by RP-HPLC coupled with evaporative light scattering detection].
2007 Nov
The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes.
2007 Nov
Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study.
2007 Nov
Glucosamine and its N-acetyl-phenylalanine derivative prevent TNF-alpha-induced transcriptional activation in human chondrocytes.
2007 Nov-Dec
Evaluation of the suppressive actions of glucosamine on the interleukin-1beta-mediated activation of synoviocytes.
2007 Oct
Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351].
2007 Oct 31
Treatment of primary and secondary osteoarthritis of the knee.
2007 Sep
Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner.
2007 Sep 21
A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial.
2008 Feb 17
Influence of glucosamine sulphate on oxidative stress in human osteoarthritic chondrocytes: effects on HO-1, p22(Phox) and iNOS expression.
2008 Jan
Sulfated glucosamine inhibits oxidation of biomolecules in cells via a mechanism involving intracellular free radical scavenging.
2008 Jan 28
Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down-regulation of mitogen-activated protein kinase-mediated nuclear factor-kappaB signaling.
2008 Mar
Disease-modifying effects of glucosamine HCl involving regulation of metalloproteinases and chemokines activated by interleukin-1beta in human primary synovial fibroblasts.
2008 May 1
Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride.
2008 Sep
Patents

Sample Use Guides

In Vivo Use Guide
In clinical studies of arthritis, glucosamine dosage has typically been 1.5 g/day, as a single dose or in divided doses.
Route of Administration: Oral
To induce insulin resistance 3T3-L1 adipocytes were treated with DMEM containing 10% FBS and 2 mM glucosamine, and in the absence of glucose, glutamine, and insulin. Since glucosamine bypasses the GFAT step to enter the hexosamine pathway, glutamine is not needed for glucosamineinduced insulin resistance
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:53:09 GMT 2023
Edited
by admin
on Sat Dec 16 08:53:09 GMT 2023
Record UNII
15VQ11I66N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLUCOSAMINE SULFATE POTASSIUM CHLORIDE
USP   WHO-DD  
Systematic Name English
D-GLUCOSE, 2-AMINO-2-DEOXY-, SULFATE, COMPD. WITH POTASSIUM CHLORIDE
Systematic Name English
GLUCOSAMINE SULFATE POTASSIUM CHLORIDE [EP MONOGRAPH]
Common Name English
GLUCOSAMINE SULFPHATE (AS POTASSIUM CHLORIDE)
Common Name English
GLUCOSAMINE SULFATE POTASSIUM CHLORIDE [USP IMPURITY]
Common Name English
D-GLUCOSE, 2-AMINO-2-DEOXY-, SULFATE, COMPD. WITH POTASSIUM CHLORIDE (2:1:2)
Systematic Name English
GLUCOSAMINE SULFATE (AS POTASSIUM CHLORIDE)
Common Name English
Glucosamine sulfate potassium chloride [WHO-DD]
Common Name English
Code System Code Type Description
CAS
1296149-08-0
Created by admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
PRIMARY
PUBCHEM
76965765
Created by admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
PRIMARY
DAILYMED
15VQ11I66N
Created by admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
PRIMARY
FDA UNII
15VQ11I66N
Created by admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
PRIMARY
EVMPD
SUB26636
Created by admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
PRIMARY
SMS_ID
100000091426
Created by admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
PRIMARY
ChEMBL
CHEMBL2110916
Created by admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
PRIMARY
RXCUI
1789517
Created by admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
PRIMARY
CAS
216699-44-4
Created by admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
PRIMARY
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY